SYK changes
Pick any two versions below to diff them.
- Price
- $291.86 → $318.79(+9.2%)
- Recent events
- Oct added: 30, 2026: In its Q3 2026 quarterly report, Stryker said that in October 2026 it agreed to invest about $400 million in cash in preferred shares of CMR Surgical, the maker of the Versius Plus surgical robot. The agreement gives Stryker the exclusive US distribution rights for the Versius products and an exclusive option to buy all of CMR Surgical later. Stryker expects the deal to close in Q4 2026, after regulatory approval. Oct 29, 2026: Stryker reported Q3 2026 results. Net sales were $6.5 billion, up 7.7%, with 7.7% organic growth. Adjusted EPS was $3.52, up 10.3%. Reported EPS fell 11.7% to $1.96, after a goodwill impairment of $293 million. Hip sales fell 1.0% and knee sales grew 1.1%. The CEO said that the quarter fell short of Stryker's expectations. Stryker cut its 2026 outlook to organic sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90. The Board added $3.0 billion to the share repurchase program. Oct 6, 2026: Stryker said that Spencer Stiles, President and COO, will become CEO on January 1, 2027. Kevin Lobo, CEO since 2012, will become Executive Chair of the Board. Stiles has worked at Stryker for 27 years and led Orthopaedics from 2019. Oct 1, 2026: Stryker said that it will report Q3 2026 results on October 29, 2026, with a call at 4:30 p.m. Eastern time. Sep 8, 2026: At a Wells Fargo conference, CFO Preston Wells said that supply problems in the peripheral vascular business may continue into Q4 2026, after Stryker had expected to solve them by Q3. He also said that hip sales were slower than expected over the summer. Stryker did not change its outlook. The stock fell about 10% by the next day. Jul 30, 2026: Stryker reported Q2 2026 results. Net sales were $6.6 billion, up 9.4%, with 9.0% organic growth. Adjusted EPS was $3.69, up 17.9%. Stryker narrowed its 2026 outlook to organic sales growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10. May 20, 2026: Stryker named Kathryn Baculik its chief accounting officer from September 1, 2026. Apr 30, 2026: Stryker reported Q1 2026 results. Net sales were $6.0 billion, up 2.6%, with 2.4% organic growth. Adjusted EPS fell 8.5% to $2.60 because of the cyberattack. Stryker kept its 2026 outlook. The stock fell about 6% the next day.